Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics Inc (NQ: TVTX )

14.34 -0.70 (-4.69%)
Streaming Delayed Price Updated: 3:09 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,882,367
Open 14.18
Bid (Size) 14.31 (2)
Ask (Size) 14.34 (3)
Prev. Close 15.04
Today's Range 13.97 - 14.90
52wk Range 5.120 - 15.36
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Where Travere Therapeutics Stands With Analysts
Via Benzinga
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga

Performance

YTD
+49.95%
+49.95%
1 Month
+58.22%
+58.22%
3 Month
+73.13%
+73.13%
6 Month
+85.93%
+85.93%
1 Year
+65.53%
+65.53%

More News

Read More
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
From Travere Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings For Travere Therapeutics
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
Via Benzinga
Expert Ratings For Travere Therapeutics
Via Benzinga
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
Via Investor's Business Daily
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Travere Therapeutics Reports Second Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Via Talk Markets
Travere Therapeutics to Report Second Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.